Trial Condition(s):

Type 2 Diabetes Mellitus

Diabetes treatment with Glucobay in combination with sulfonylurea

Bayer Identifier:

13927

ClinicalTrials.gov Identifier:

NCT01613105

EudraCT Number:

Not Available

Study Completed

Trial Purpose

In this prospective, non interventional, observational Post Marketing Survelliance study data are obtained on the efficacy, safety and tolerability of Glucobay treatment on top of sulfonylurea under daily life treatment conditions.Specifically investigated is the influence of Glucobay on Post Prandial Blood Glucose and HbA1c as well as on pateint's weight when added to an already existing sulfonylurea therapy.The study is planned to carried out in 25000 - 30000 patients from 200 trial sites in India.The Post Marketing Survelliance study will be performed with commercially available medication prescribed within regular practice of the physician. No other examination will be performed than would be done without Post Marketing Survelliance study.

Inclusion Criteria
- All patient with type 2 diabetes with one of the following treatment ongoing : 1) Sulfonylurea 
2) Sulfonylurea + OHA.
In such patients, if investigator feels that addition of acarbose would be benficial for the patients
Exclusion Criteria
- According to local  product information

Trial Summary

Enrollment Goal
4564
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Acarbose (Precose/Glucobay, BAYG5421)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, India

Status
Completed
 

Trial Design